With a staff of almost 50 digital pathology experts, Visiopharm A/S and LRI Imaging AB are jointly becoming a highly specialized European leader in Diagnostic Digital Pathology solutions. “We are now seeing diagnostic digital pathology take off; and not just in Scandinavia, but in large parts of Europe. An important experience from the last 10 years is that going digital is a major undertaking for the pathology lab. We are excited about this merger, which allow us to offer our joint experience and expertise in helping diagnostic pathology labs going digital - one cost-efficient and risk-free step at a time. Our joint expertise gives us a depth of practical expertise in all critical aspects of digital pathology, allowing us to become a true partner in helping pathology labs both implement and take full advantage of this type of technology”, says Michael Grunkin CEO of Visiopharm
Rickard Lindelöf, CEO of LRI Imaging / Visiopharm AB, adds: “For almost a decade we have provided diagnostic digital pathology solutions to Swedish pathology labs. We have done that by integrating best-of-breed solution components. The technology developed by Visiopharm allow us to finally realize the full potential of diagnostic digital pathology: Integrating image analysis in LIS-driven workflows, which is giving pathologists access to validated technology that will improve both data quality and productivity while reducing costs and turnaround times”.
“We have been running several large clinical studies using this technology, of which some have already been published. That has allowed us to see firsthand to what extent image analysis, if used in the right way, can give significant improvements in diagnostic data quality. We believe this will have a great impact on patient safety. And we are excited to see such technology integrated in an open end-to-end digital pathology solution. We are convinced that digital pathology will lead to improvements in the patient care and help us cope with the growing case load and complexity all diagnostic labs are experiencing. This will benefit both patients individually and society in general”, says Johan Hartmann, Professor at Karolinska University Hospital.